BOSTON, Mass. (TheStreet) -- Here is June's calendar of important, potentially stock-moving biotech events:

May 29-June 3

The American Urological Association annual meeting.

June 2

FDA advisory panel meets to review AstraZeneca's ( AZN - Get Report) Numax for respiratory syncytial virus.

June 3

BioDelivery Sciences ( BDSI) analyst/investor meeting.

Johnson & Johnson ( JNJ) analyst/investors meeting.

June 4-8

The American Society of Clinical Oncology (ASCO) annual meeting. Data presentation expected from Celldex Therapeutics ( CLDX - Get Report), Ziopharm ( ZIOP), Delcath Systems ( DCTH), Pfizer ( PFE - Get Report), Celgene ( CELG - Get Report) -- and too many other companies to mention here.
More on Biotech
14 Biotech Stocks Facing FDA Approval

June 4

Cell Therapeutics ( CTIC - Get Report) annual shareholder meeting.

June 10

FDA advisory panel meets to review Novartis' ( NVS - Get Report) oral multiple sclerosis drug Gilenia. FDA's briefing materials should be posted to the agency's web site on June 8. The Gilenia panel is also important for Biogen Idec ( BIIB), Teva ( TEVA) and Merck-Serono, which market current injectable MS drugs.

June 10-13

European Hematological Association meeting.

June 11

FDA approval decision date for Questcor Pharmaceuticals' ( QCOR) Acthar Gel for infantile spasms.

June 16

Genzyme ( GENZ) annual shareholder meeting.

June 16-19

European League Against Rheumatism meeting. Lupus data presentations from Human Genome Sciences ( HGSI) and UCB/ Immunomedics ( IMMU).

International Society for Stem Cell Research meeting.

June 18

FDA advisory panel meets to review Boehringer Ingelheim's filbanserin for the treatment of female sexual dysfunction. The filbanserin panel could also impact Biosante Pharmaceuticals ( BPAX) and its competing female libido drug LibiGel, currently in phase III studies.

June 24

FDA approval decision date for AstraZeneca's Numax for respiratory syncytial virus.

Ligand Pharmaceuticals ( LGND) analyst/investor day.

June 25-29

American Diabetes Association annual meeting.

Sometime in June

Phase III study results from Affymax's ( AFFY) anemia drug Hematide.

-- Reported by Adam Feuerstein in Boston.
More Biotech Stocks
14 Biotech Stocks Facing FDA Approval

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.